RESUMEN
BACKGROUND: Since the outbreak of a new emerging virulent pseudorabies virus mutant in Chinese pig herds, intensive research has been focused on the construction of novel gene deletion vaccine based on the variant virulent viruses. An ideal vaccine candidate is expected to have a balanced safety and immunogenicity. RESULTS: From the infectious clone of PRV AH02LA strain, a TK deletion mutant was generated through two-step Red mutagenesis. After homologous recombination with a transfer vector, a TK&gE dual deficient mutant PRV (PRVΔTK&gE-AH02) was generated, and its structure verified by PCR, RFLP and sequencing. Growth kinetics test showed that PRVΔTK&gE-AH02 reached a titer of 107.5 TCID50 /mL on ST cells. The PRVΔTK&gE-AH02 at a dose of 106.0 TCID50 /animal was not virulent in mice or 1-day-old piglets with maternal PRV antibodies. No clinical signs or virus shedding were detected in 28~ 35-day-old piglets without maternal PRV antibodies after nasal or intramuscular administration with a dose of 106.0 TCID50, although it caused one death of four 1-day-old piglets without maternal PRV antibodies. In the efficiency test of PRVΔTK&gE-AH02, all four 28~ 35-day-old piglets without PRV antibody in the challenge control showed typical clinical symptoms and virus shedding, and two died at 4~ 5 days post challenge. All piglets in 105.0, 104.0 and 103.0 TCID50/dose PRVΔTK&gE-AH02 groups provided complete protection against challenge at only 7 days post intramuscular vaccination. More importantly, PRVΔTK&gE-AH02 stopped virus shedding in these piglets. In contrast, all four piglets in PRV Bartha K61 vaccine group developed high body temperature (≥40.5 °C) and viral shedding, despite they had mild or even no clinical symptoms. CONCLUSIONS: The constructed TK&gE dual deletion mutant PRVΔTK&gE-AH02 can reach high titers on ST cells. The live vaccine of PRVΔTK&gE-AH02 is highly safe, and can not only provide clinical protection but also stops virus shedding. This study suggests that PRVΔTK&gE-AH02 might work as a promising vaccine candidate to combat the PRV variant emerging in Chinese herds since 2011.
Asunto(s)
Herpesvirus Suido 1/genética , Herpesvirus Suido 1/inmunología , Vacunas contra la Seudorrabia/administración & dosificación , Seudorrabia/prevención & control , Enfermedades de los Porcinos/prevención & control , Animales , Anticuerpos Antivirales/sangre , Ratones , Porcinos , Vacunas Atenuadas , Proteínas del Envoltorio ViralRESUMEN
The effect of a seven-day antibiotic therapy with doxycycline was investigated on the postvaccinal humoral and cellular immune response in pigs. The selected parameters of non-specific immunity were also studied. Fifty pigs were used (control not vaccinated (C, n=10), control vaccinated (CV, n=20), and experimental - received doxycycline (DOXY, n=20)). For vaccination live-attenuated vaccine against pseudorabies (PR) was used. From day -1 to day 5 pigs from DOXY group received doxycycline orally with drinking water, at the recommended dose. Pigs from DOXY and CV groups were vaccinated at 8 and 10 weeks of age. The results of the present study showed that cell-mediated postvaccinal immune response can be modulated by oral treatment with doxycycline. Significantly lower values of stimulation index were observed after PRV restimulation in doxycycline-treated pigs. Moreover, in the DOXY group a significant decrease in IFN-γ production after PRV restimulation was noted. The significantly lower number of CD4+CD8+ cells was also observed in doxy-treated, vaccinated pigs, 2 weeks after final vaccination. Simultaneously, specific humoral response was not disturbed. This study demonstrated the importance of defining the immune modulatory activity of doxycycline because it may alter the immune responses to vaccines. The exact mechanism of T-cell response suppression by doxycycline remains to be elucidated, however the influence of doxycycline on the secretion of various cytokines, including IFN-γ, may be considered as a possible cause. The present observations should prompt further studies on the practical significance of such phenomena in terms of clinical implications.
Asunto(s)
Antibacterianos/farmacología , Doxiciclina/farmacología , Inmunidad Celular/efectos de los fármacos , Inmunidad Humoral/efectos de los fármacos , Vacunas contra la Seudorrabia/inmunología , Proteínas de Fase Aguda/metabolismo , Animales , Antibacterianos/administración & dosificación , Anticuerpos Antivirales/sangre , Recuento de Linfocito CD4 , Linfocitos T CD8-positivos/efectos de los fármacos , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/virología , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Doxiciclina/administración & dosificación , Esquema de Medicación , Interacciones Farmacológicas , Femenino , Interferón gamma/metabolismo , Interleucina-4/metabolismo , Activación de Linfocitos/efectos de los fármacos , Masculino , Modelos Animales , Vacunas contra la Seudorrabia/administración & dosificación , Sus scrofa , Células TH1/efectos de los fármacos , Células TH1/inmunología , Células TH1/virología , Células Th2/efectos de los fármacos , Células Th2/inmunología , Células Th2/virología , Factores de Tiempo , Vacunación , Vacunas Atenuadas/inmunologíaRESUMEN
In recent years, pseudorabies virus (PRV) variants have resulted in an epidemic in swine herds and huge economic losses in China. Therefore, it is essential to develop an efficacious vaccine against the spread of PRV variants. Here, the triple-gene-deletion virus and the triple-gene-deletion plus gC virus were constructed by homologous recombination (HR). And then, their growth capacity, proliferation ability, and immune efficacy were evaluated. The results showed that the growth kinetics of the recombinant viruses were similar to those of the parental strain PRV-AH. Compared with the triple-gene-deletion virus group, the more dominant level of neutralizing antibody (NA) can be induced in the triple-gene-deletion plus gC virus group with the same 106.0 TCID50 dose after 4 and 6 weeks post-initial immunization (PII) (p < 0.0001). In addition, the antibody titers in mice immunized with the triple-gene-deletion plus gC virus were significantly higher than those immunized with triple-gene deletion virus with the same 105.0 TCID50 dose after 6 weeks PII (p < 0.001). More importantly, in the triple-gene-deletion plus gC virus group with 105.0 TCID50, the level of NA was close to that in the triple-gene deletion virus group with 106.0 TCID50 at 6 weeks PII. Meanwhile, the cytokines IL-4 and IFN-γ in sera were tested by enzyme-linked immunosorbent assay (ELISA) in each group. The highest level of IL-4 or IFN-γ was also elicited in the triple-gene deletion plus gC virus group at a dose of 106.0 TCID50. After challenge with PRV-AH, the survival rates of the triple-gene deletion plus gC virus immunized groups were higher than those of other groups. In immunized groups with 105.0 TCID50, the survival rate shows a significant difference between the triple-gene deletion plus gC virus group (75%, 6/8) and the triple-gene deletion virus group (12.5%, 1/8). In general, the immune efficacy of the PRV TK/gI/gE-deleted virus can be increased with additional gC insertion in mice, which has potential for developing an attenuated vaccine candidate for PRV control.
Asunto(s)
Anticuerpos Neutralizantes , Anticuerpos Antivirales , Eliminación de Gen , Herpesvirus Suido 1 , Vacunas contra la Seudorrabia , Seudorrabia , Animales , Herpesvirus Suido 1/genética , Herpesvirus Suido 1/inmunología , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Ratones , Anticuerpos Neutralizantes/sangre , Anticuerpos Neutralizantes/inmunología , Seudorrabia/prevención & control , Seudorrabia/inmunología , Seudorrabia/virología , Vacunas contra la Seudorrabia/inmunología , Vacunas contra la Seudorrabia/genética , Vacunas contra la Seudorrabia/administración & dosificación , Ratones Endogámicos BALB C , Porcinos , Femenino , Proteínas del Envoltorio Viral/genética , Proteínas del Envoltorio Viral/inmunología , Recombinación Homóloga , Citocinas/metabolismo , ChinaRESUMEN
Pseudorabies virus (PRV) is a highly contagious viral disease, which leads to severe financial losses in the breeding industry worldwide. Presently, PRV is mainly controlled using live attenuated and inactivated vaccines. However, these vaccines have an innate tendency to lose their structural conformation upon exposure to environmental and chemical stressors and cannot provide full protection against the emerging prevalent PRV variants. In this work, first, we synthesized aminated ZIF-7/8 nanoparticles (NPs), and then chemical bond-coated alginate dialdehyde (ADA, a type of dioxide alginate saccharide) on their surface via Schiff base reaction to obtain ZIF-7/8-ADA NPs. The as-fabricated ZIF-7/8-ADA NPs exhibited high stability, monodispersity and a high loading ratio of antigen. Furthermore, the ZIF-7/8-ADA NPs showed good biocompatibility in vitro and in vivo. Using ZIF-7/8-ADA NPs as an adjuvant and inactivated PRV as a model antigen, we constructed a PR vaccine through a simple mixture. The immunity studies indicated that ZIF-7/8-ADA induced an enhancement in the Th1/Th2 immune response, which was superior to that of the commercial ISA201, alum adjuvant and ZIF-7/8. Due to the pH-sensitive release of the antigen in lysosomes, the as-prepared PR vaccine subsequently accelerated the antigen presentation and improved the immune responses in vitro and in vivo. The results of PRV challenge using mice as the model demonstrated that ZIF-7/8-ADA achieved the same preventive effect as the commercial ISA201 and was much better than the alum adjuvant, and thus can serve as a promising delivery system and adjuvant to enhance humoral and cellular responses against PRV infection.
Asunto(s)
Adyuvantes Inmunológicos , Alginatos , Estructuras Metalorgánicas , Nanopartículas , Animales , Alginatos/química , Alginatos/farmacología , Ratones , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/farmacología , Estructuras Metalorgánicas/química , Estructuras Metalorgánicas/farmacología , Seudorrabia/prevención & control , Seudorrabia/inmunología , Herpesvirus Suido 1/inmunología , Vacunas contra la Seudorrabia/inmunología , Vacunas contra la Seudorrabia/administración & dosificación , Vacunas de Productos Inactivados/inmunología , Vacunas de Productos Inactivados/administración & dosificación , Portadores de Fármacos/química , Vacunación/métodos , Ratones Endogámicos BALB C , FemeninoRESUMEN
The co-administration of two or more cytokines may generate additive or synergistic effects for controlling infectious diseases. However, the practical use of cytokine combinations for the modulation of immune responses against inactivated vaccine has not been demonstrated in livestock yet, primarily due to protein stability, production, and costs associated with mass administration. In light of the current situation, we evaluated the immunomodulatory functions of the combined administration of swine interleukin-18 (swIL-18) and interferon-α (swIFN-α) against an inactivated PrV vaccine using attenuated Salmonella enterica serovar Typhimurium as a cytokine delivery system. Co-administration of S. enterica serovar Typhimurium expressing swIL-18 and swIFN-α produced enhanced Th1-biased humoral and cellular immune responses against the inactivated PrV vaccine, when compared to single administration of S. enterica serovar Typhimurium expressing either swIL-18 or swIFN-α. Also, enhanced immune responses in co-administered piglets occurred rapidly after virulent PrV challenge, and piglets that received co-administration of S. enterica serovar Typhimurium expressing swIL-18 and swIFN-α displayed a greater alleviation of clinical severity following the virulent PrV challenge, as determined by clinical scores and cumulative daily weight gain. Furthermore, this enhancement was confirmed by reduced nasal shedding of PrV following viral challenge. Therefore, these results suggest that oral co-administration of S. enterica serovar Typhimurium expressing swIL-18 and swIFN-α provide enhanced Th1-biased immunity against inactivated PrV vaccine to alleviate clinical signs caused by PrV challenge.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Vectores Genéticos/administración & dosificación , Herpesvirus Suido 1/inmunología , Interferón-alfa/administración & dosificación , Interleucina-18/administración & dosificación , Vacunas contra la Seudorrabia/inmunología , Células TH1/inmunología , Animales , Peso Corporal , Modelos Animales de Enfermedad , Inmunidad Celular , Inmunidad Humoral , Interferón-alfa/genética , Interleucina-18/genética , Seudorrabia/inmunología , Seudorrabia/patología , Seudorrabia/prevención & control , Vacunas contra la Seudorrabia/administración & dosificación , Salmonella typhimurium/genética , Índice de Severidad de la Enfermedad , Porcinos , Vacunas de Productos Inactivados/administración & dosificación , Vacunas de Productos Inactivados/inmunologíaRESUMEN
Pseudorabies virus (PRV) is a major pathogen in pig husbandry and is also a risk to human well-being. Pigs with latent PRV infection carry the virus lifelong, and it can be activated under conducive conditions. This poses a very important challenge to the control of the virus and may even prevent its elimination. To investigate latent infection with wild-type (wt) PRV, and also infection due to the use of live attenuated vaccines on farms, 80 pigs from two large-scale swine operations were traced. At 6 months old, the quarantined pigs were slaughtered and brain samples were collected. A PCR assay targeting the gB and gE genes was developed to detect PRV DNA fragments in medulla oblongata. Five of the samples (6.3%) were gB and gE gene fragment double-positive, 60 of the samples (75%) were gB single-positive, and 15 samples (18.7%) showed double-negative. A portion of latency-associated transcripts (LATs), EP0 mRNA, were found to be present in the gB gene fragment positive samples. Furthermore, the five double-positive samples were transmitted blindly, and apparent cytopathic effects were found in three of the five samples in the fourth generation. By means of Western blotting, PCR and sequencing, two of the isolated viruses were found to be related to vaccine strain Bartha-K61. Another was closely related to domestic epidemic strains HN1201 and LA and relatively unrelated to other Asian isolates. These results suggest that the live vaccines are latently present in brains, in a manner similar to wt PRV, and this poses potential safety issues in the pig husbandry industry. Wt PRV and live vaccine viruses were found to co-exist in pigs, demonstrating that the live vaccines were unable to confer complete sterilizing immunity, which may explain outbreaks of pseudorabies on vaccinated farms.
Asunto(s)
Herpesvirus Suido 1/aislamiento & purificación , Infección Latente/veterinaria , Bulbo Raquídeo/virología , Vacunas contra la Seudorrabia/metabolismo , Seudorrabia/virología , Cuarentena/veterinaria , Enfermedades de los Porcinos/virología , Animales , China , Infección Latente/virología , Vacunas contra la Seudorrabia/administración & dosificación , Sus scrofa , Porcinos , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/metabolismoRESUMEN
Pseudorabies has caused huge economic losses in China's pig industry and recurred on many large pig farms since late 2011. The disease is caused by highly pathogenic, antigenic variant pseudorabies virus (vPRV) strains. Therefore, the prevention and control of this recurrence of pseudorabies in China has been given priority. In a previous study, we showed that a suitable dose [1â¯×â¯106.3 50% tissue culture infectious dose (TCID50) per animal] of commercial Bartha-K61 vaccine protects growing pigs against lethal challenge by the emerging vPRV strain XJ5. In this study, different doses of the Bartha-K61 vaccine and our newly developed rPRV-gI-/gE-/TK- prototype vaccine derived from the vPRV strain XJ5 were used to evaluate immune protection against sublethal challenge by the vPRV strain XJ5. Pigs vaccinated with high doses of the Bartha-K61 vaccine or rPRV-gI-/gE-/TK- prototype vaccine showed no differences in their humoral immune responses, clinical symptoms, body weight gains, viral shedding, or gross and histological lesions after sublethal challenge by the vPRV strain XJ5. Therefore, we concluded that the Bartha-K61 vaccine at a dose of 1â¯×â¯105 TCID50 per animal protects pigs against sublethal challenge by the vPRV strain XJ5 and performs equally well as the same dose of the rPRV-gI-/gE-/TK- vaccine, whereas lower doses of the Bartha-K61 vaccine alone do not protect pigs from this challenge. These findings provide useful information for vaccination interventions and the ultimate eradication of pseudorabies caused by vPRV strains emerging in China.
Asunto(s)
Vacunas contra la Seudorrabia/administración & dosificación , Seudorrabia/prevención & control , Enfermedades de los Porcinos/prevención & control , Animales , Relación Dosis-Respuesta Inmunológica , Herpesvirus Suido 1/inmunología , Seudorrabia/virología , Vacunas contra la Seudorrabia/clasificación , Porcinos , Enfermedades de los Porcinos/virologíaRESUMEN
The prevalence of an emerging variant of the pseudorabies virus (PRV) has been causing serious losses to farmers in China. Moreover, the commercially available PRV vaccine often fails to provide thorough protection. Therefore, in this study, we generated a PRV-∆gC\gE∆TK strain with defects in gC, gE, and TK of PRV. Compared to the parental PRV strain and the single gene deletion strains (PRV-∆gC, PRV-∆gE, and PRV-∆TK), PRV-∆gC\gE∆TK grew slowly, and exhibited fewer and smaller plaques on swine testis (ST) cells. Furthermore, animal experiment results showed that mice that were immunized intramuscularly with PRV-∆gC\gE∆TK, survived throughout the experiment with no observed clinical symptoms, and were completely protected against PRV challenge. Additionally, deletion of the gC, gE, and TK genes significantly alleviated viral damage in the brain. Furthermore, one-day-old weaned piglets immunized intramuscularly with PRV-∆gC\gE∆TK elicited higher levels of gB antibodies against both the emerging PRV variant and the parental PRV, exhibited full protection against challenge with both variants, and showed neutralization capacity against PRV. These data suggest that PRV-∆gC\gE∆TK is a promising vaccine candidate for the control of pseudorabies.
Asunto(s)
Herpesvirus Suido 1/genética , Herpesvirus Suido 1/inmunología , Vacunas contra la Seudorrabia/administración & dosificación , Seudorrabia/prevención & control , Enfermedades de los Porcinos/prevención & control , Animales , Sistemas CRISPR-Cas , Eliminación de Gen , Genes Virales , Células HEK293 , Humanos , Inmunización , Inyecciones Intramusculares , Ratones Endogámicos BALB C , Seudorrabia/virología , Vacunas contra la Seudorrabia/inmunología , Porcinos , Enfermedades de los Porcinos/virología , Vacunas AtenuadasRESUMEN
Messenger RNA-based vaccines represent new tools with prophylactic and therapeutic potential characterized by high flexibility of application for infectious diseases. Pseudorabies virus (PRV) is one of the major viruses affecting the pig industry. PRV has serious effects in piglets, sows, and growing-fattening pigs and can lead to huge economic losses. In this study, an envelope glycoprotein D (gD) gene-based specific mRNA vaccine was generated, and a mouse model was used to investigate the protective efficacy of the vaccine. The gD mRNA vaccine and the recombinant plasmid pVAX-gD were transfected into BHK21 cells, and the antigenicity of the expressed proteins was detected by Western blot analysis. Groups of mice were vaccinated with the gD mRNA vaccine, pVAX-gD, and PBS. T cell immune responses were measured by flow cytometry or ELISA and serum neutralization tests every two weeks. The challenge with the PRV-XJ strain was performed eight weeks after the primary immunization, and the response was monitored for 15 days. The levels of specific and neutralizing antibodies in the gD mRNA vaccine group were significantly increased in 8 weeks compared to those in the control group, and cytokine levels, including that of IFN-γ/IL-2, were considerably higher than those in the control animal. Additionally, the proportion of CD4+/CD8+ cells in peripheral lymphocytes was remarkably increased. Our data demonstrate that mRNA is a promising and effective tool for the development of vaccines. The PRV-gD-based mRNA vaccine can elicit an efficient neutralizing antibody response and induce effective protection in mice in defense against PRV infection.
Asunto(s)
Anticuerpos Antivirales/sangre , Herpesvirus Suido 1/inmunología , Vacunas contra la Seudorrabia/inmunología , Seudorrabia/prevención & control , Vacunas Sintéticas/inmunología , Proteínas del Envoltorio Viral/inmunología , Animales , Anticuerpos Neutralizantes/sangre , Línea Celular , Cricetinae , Femenino , Riñón/citología , Ratones , Ratones Endogámicos BALB C , Seudorrabia/inmunología , Vacunas contra la Seudorrabia/administración & dosificación , Porcinos , Enfermedades de los Porcinos/inmunología , Enfermedades de los Porcinos/prevención & control , Enfermedades de los Porcinos/virología , Transfección , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/genética , Proteínas del Envoltorio Viral/genética , Vacunas de ARNmRESUMEN
Molecular adjuvants are vaccine delivery vehicle to increase specific antigens effectiveness. Herein, we concentrated on IgG Fc, an effective molecular adjuvant, to develop novel pseudorabies virus (PRV) subunit vaccines. Two major protective antigen genes of PRV were constructed and linked into the mouse IgG Fc fragment. The gD, gD-IgG2aFc, gB and gB-IgG2aFc proteins were expressed using a baculovirus system. Mice intranasally immunized with gD-IgG2aFc or gB-IgG2aFc subunit vaccine exhibited significantly higher PRV-specific antibodies, neutralizing antibodies and intracellular cytokines than the mice intranasally immunized with gD or gB subunit vaccine. Moreover, no histopathological lesions were observed in mice immunized with gB-IgG2aFc subunit vaccine via histopathology examination. Further, the gB-IgG2aFc subunit vaccine was efficient for PRV infection compared with live attenuated vaccine. Overall, these results suggest that IgG2a Fc fragment, as a potential molecular adjuvant, fused with PRV antigen might be a promising and efficient PRV vaccine candidate.
Asunto(s)
Herpesvirus Suido 1/efectos de los fármacos , Fragmentos Fc de Inmunoglobulinas/biosíntesis , Vacunas contra la Seudorrabia/biosíntesis , Seudorrabia/prevención & control , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas del Envoltorio Viral/biosíntesis , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/biosíntesis , Adyuvantes Inmunológicos/genética , Animales , Anticuerpos Antivirales/biosíntesis , Baculoviridae/genética , Baculoviridae/metabolismo , Citocinas/genética , Citocinas/inmunología , Células Epiteliales/patología , Células Epiteliales/virología , Femenino , Glicoproteínas/administración & dosificación , Glicoproteínas/biosíntesis , Glicoproteínas/genética , Herpesvirus Suido 1/genética , Herpesvirus Suido 1/inmunología , Herpesvirus Suido 1/patogenicidad , Inmunización , Fragmentos Fc de Inmunoglobulinas/administración & dosificación , Fragmentos Fc de Inmunoglobulinas/genética , Inmunoglobulina G/administración & dosificación , Inmunoglobulina G/biosíntesis , Inmunoglobulina G/genética , Riñón/patología , Riñón/virología , Ratones , Ratones Endogámicos BALB C , Seudorrabia/inmunología , Seudorrabia/mortalidad , Seudorrabia/virología , Vacunas contra la Seudorrabia/administración & dosificación , Vacunas contra la Seudorrabia/genética , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/genética , Análisis de Supervivencia , Porcinos , Vacunas de Subunidad , Proteínas del Envoltorio Viral/administración & dosificación , Proteínas del Envoltorio Viral/genéticaRESUMEN
The major immunodominant surface antigen 1 (TgSAG1) of invasive tachyzoites is a vaccine candidate antigen for Toxoplasma gondii. In this study, we developed a recombinant pseudorabies virus (PRV) expressing TgSAG1 (rPRV/SAG1) based on the PRV vaccine strain Bartha K-61 by homologous recombination, in which partial PK and gG genes were deleted. The growth assay of rPRV/SAG1 showed that the recombinant virus can replicate in vitro as efficiently as PRV Bartha K-61, demonstrating that insertion of the TgSAG1 gene in the PK and gG locus of PRV does not affect the replication of PRV. All mice vaccinated with rPRV/SAG1 developed a high level of specific antibody responses against T. gondii lysate antigen (TLA), a strong increase of the splenocyte proliferative response, and significant levels of IFN-gamma and IL-2 production. And the immunization of mice with rPRV/SAG1 elicited strong cytotoxic T lymphocyte (CTL) responses in vitro. These results demonstrate that rPRV/SAG1 could induce significant humoral and cellular Th1 immune responses. Moreover, rPVR/SAG1 immunization induced partial protection (60%) against a lethal challenge with the highly virulent T. gondii RH strain, and neutralizing antibodies against PRV in a BALB/c mouse model. These results suggest that expression of protective antigens of T. gondii in PRV Bartha K-61 is a novel approach towards the development of a vaccine against both animal toxoplasmosis and pseudorabies.
Asunto(s)
Antígenos de Protozoos , Herpesvirus Suido 1 , Proteínas Protozoarias , Seudorrabia/prevención & control , Recombinación Genética , Toxoplasmosis Animal/prevención & control , Animales , Anticuerpos Antiprotozoarios/sangre , Anticuerpos Antivirales/sangre , Antígenos de Protozoos/genética , Antígenos de Protozoos/inmunología , Antígenos de Protozoos/metabolismo , Herpesvirus Suido 1/genética , Herpesvirus Suido 1/inmunología , Herpesvirus Suido 1/metabolismo , Herpesvirus Suido 1/patogenicidad , Activación de Linfocitos , Ratones , Ratones Endogámicos BALB C , Proteínas Protozoarias/genética , Proteínas Protozoarias/inmunología , Proteínas Protozoarias/metabolismo , Vacunas Antiprotozoos/administración & dosificación , Vacunas Antiprotozoos/genética , Vacunas Antiprotozoos/inmunología , Seudorrabia/inmunología , Seudorrabia/virología , Vacunas contra la Seudorrabia/administración & dosificación , Vacunas contra la Seudorrabia/genética , Vacunas contra la Seudorrabia/inmunología , Toxoplasma/genética , Toxoplasma/inmunología , Toxoplasma/metabolismo , Toxoplasma/patogenicidad , Toxoplasmosis Animal/inmunología , Toxoplasmosis Animal/parasitología , Vacunación , Vacunas de ADN/administración & dosificación , Vacunas de ADN/genética , Vacunas de ADN/inmunologíaRESUMEN
Replication-incompetent adenoviruses expressing three major glycoproteins (gB, gC, and gD) of pseudorabies virus (PrV) were constructed and used to examine the ability of these glycoproteins to induce protective immunity against a lethal challenge. Among three constructs, recombinant adenovirus expressing gB (rAd-gB) was found to induce the most potent immunity biased to Th1-type, as determined by the IgG isotype ratio and the profile of the Th1/Th2 cytokine production. Conversely, the gC-expressing adenovirus (rAd-gC) revealed Th2-type immunity and the gD-expressing adenovirus (rAd-gD) induced lower levels of IFN-? and IL-4 production than other constructs, except IL-2 production. Mucosal delivery of rAd-gB induced mucosal IgA and serum IgG responses and biased toward Th2-type immune responses. However, these effects were not observed in response to systemic delivery of rAd-gB. In addition, rAd-gB appeared to induce effective protective immunity against a virulent viral infection, regardless of whether it was administered via the muscular or systemic route. These results suggest that administration of replication-incompetent adenoviruses can induce different types of immunity depending on the expressed antigen and that recombinant adenoviruses expressing gB induced the most potent Th1-biased humoral and cellular immunity and provided effective protection against PrV infection.
Asunto(s)
Adenoviridae/inmunología , Glicoproteínas/inmunología , Herpesvirus Suido 1/inmunología , Vacunas contra la Seudorrabia/inmunología , Seudorrabia/inmunología , Replicación Viral , Adenoviridae/genética , Adenoviridae/metabolismo , Animales , Formación de Anticuerpos , Línea Celular , Citocinas/inmunología , Femenino , Glicoproteínas/biosíntesis , Glicoproteínas/genética , Herpesvirus Suido 1/genética , Herpesvirus Suido 1/fisiología , Inmunidad Celular , Inmunoglobulina G/inmunología , Ratones , Ratones Endogámicos C57BL , Seudorrabia/prevención & control , Vacunas contra la Seudorrabia/administración & dosificación , Porcinos , Células TH1/inmunología , Células Th2/inmunologíaRESUMEN
A murine model immunized by systemic and mucosal delivery of plasmid DNA vaccine expressing glycoprotein B (pCIgB) of pseudorabies virus (PrV) was used to evaluate both the nature of the induced immunity and protection against a virulent virus. With regard to systemic delivery, the intramuscular (i.m.) immunization with pCIgB induced strong PrV-specific IgG responses in serum but was inefficient in generating a mucosal IgA response. Mucosal delivery through intranasal (i.n.) immunization of pCIgB induced both systemic and mucosal immunity at the distal mucosal site. However, the levels of systemic immunity induced by i.n. immunization were less than those induced by i.m. immunization. Moreover, i.n. genetic transfer of pCIgB appeared to induce Th2-biased immunity compared with systemic delivery, as judged by the ratio of PrV-specific IgG isotypes and Th1- and Th2-type cytokines produced by stimulated T cells. Moreover, the immunity induced by i.n. immunization did not provide effective protection against i.n. challenge of a virulent PrV strain, whereas i.m. immunization produced resistance to viral infection. Therefore, although i.n. immunization was a useful route for inducing mucosal immunity at the virus entry site, i.n. immunization did not provide effective protection against the lethal infection of PrV.
Asunto(s)
Herpesvirus Suido 1/inmunología , Vacunas contra la Seudorrabia/administración & dosificación , Seudorrabia/prevención & control , Vacunas de ADN/administración & dosificación , Proteínas del Envoltorio Viral/inmunología , Administración Intranasal , Animales , Anticuerpos Antivirales/sangre , Línea Celular , Citocinas/sangre , Femenino , Herpesvirus Suido 1/genética , Herpesvirus Suido 1/patogenicidad , Inmunoglobulina A/sangre , Inmunoglobulina A Secretora , Inmunoglobulina G/sangre , Inyecciones Intramusculares , Ratones , Ratones Endogámicos C57BL , Seudorrabia/inmunología , Células TH1/inmunología , Células Th2/inmunología , Vacunas de ADN/inmunología , Proteínas del Envoltorio Viral/genéticaRESUMEN
The prime-boost vaccination with DNA vaccine and recombinant viral vector has emerged as an effective prophylactic strategy to control infectious diseases. Here, we compared the protective immunities induced by multiple alternating immunizations with DNA vaccine (pCIgB) and replication-incompetent adenovirus (Ad-gB) expressing glycoprotein gB of pseudorabies virus (PrV). The platform of pCIgB-prime and Ad-gB-boost induced the most effective immune responses and provided protection against virulent PrV infection. However, priming with pCIgB prior to vaccinating animals by the DNA vaccine-prime and Ad-boost protocol provided neither effective immune responses nor protection against PrV. Similarly, boosting with Ad-gB following immunization with DNA vaccine-prime and Ad-boost showed no significant responses. Moreover, whereas the administration of Ad-gB for primary immunization induced Th2-type-biased immunity, priming with pCIgB induced Th1-type-biased immunity, as judged by the production of PrV-specific IgG isotypes and cytokine IFN-gamma. These results indicate that the order and injection frequency of vaccine vehicles used for heterologous prime-boost vaccination affect the magnitude and nature of the immunity. Therefore, our demonstration implies that the prime-boost protocol should be carefully considered and selected to induce the desired immune responses.
Asunto(s)
Adenoviridae/metabolismo , Expresión Génica , Herpesvirus Suido 1/inmunología , Vacunas contra la Seudorrabia/administración & dosificación , Seudorrabia/prevención & control , Vacunación , Vacunas de ADN/administración & dosificación , Proteínas del Envoltorio Viral/inmunología , Adenoviridae/genética , Animales , Anticuerpos Antivirales/sangre , Linfocitos T CD4-Positivos/inmunología , Línea Celular , Citocinas/inmunología , Femenino , Herpesvirus Suido 1/genética , Humanos , Ratones , Ratones Endogámicos BALB C , Seudorrabia/inmunología , Seudorrabia/virología , Vacunas contra la Seudorrabia/genética , Vacunas contra la Seudorrabia/inmunología , Vacunación/métodos , Vacunas de ADN/genética , Vacunas de ADN/inmunología , Proteínas del Envoltorio Viral/genética , Replicación ViralRESUMEN
In late 2011, a variant pseudorabies virus (vPRV) emerged in Bartha-K61-vaccinated pig herds, resulting in high morbidity and mortality of piglets in China. Since 2013, the autopsy lesions, histological examinations, virus isolation, phylogenetic analysis and selection pressure analysis of the gE gene of vPRV were recorded for 395 clinical cases, and 5,033 pig serum samples were detected by PRV gE-coated enzyme-linked immunosorbent assay. The major clinical symptoms were abortion in pregnant sows, fatal neurological signs in piglets and respiratory disease in growing pigs. Necrotic splenitis, hepatitis and lymphadenitis, haemorrhagic nephritis and non-suppurative encephalitis were observed by histopathological examination. Typical eosinophilic inclusion bodies were found in the nuclei of liver cells. Using PCR, 110 samples among 395 clinical cases tested positive for the gE gene. Fifteen vPRV strains were isolated and confirmed by sequencing and phylogenetic analysis of the gE gene. The strains shared 97.1%-99.9% nucleotide (nt) and 96.6%-99.5% amino acid (aa) homology with PRV reference strains. Selection pressure analysis showed that one site in the codons of glycoprotein E was under positive selection. Of the 5,033 serum samples, 2,909 were positive by ELISA for a positive rate of 57.8%. These results showed that vPRV was still prevalent in Shandong Province, indicating severe PRV infectious pressure. The preparation of new vaccines against PRV is extremely urgent.
Asunto(s)
Herpesvirus Suido 1/aislamiento & purificación , Seudorrabia/epidemiología , Enfermedades de los Porcinos/epidemiología , Animales , China/epidemiología , ADN Viral/genética , Ensayo de Inmunoadsorción Enzimática/veterinaria , Estudios Epidemiológicos , Herpesvirus Suido 1/genética , Filogenia , Reacción en Cadena de la Polimerasa/veterinaria , Seudorrabia/prevención & control , Seudorrabia/virología , Vacunas contra la Seudorrabia/administración & dosificación , Porcinos , Enfermedades de los Porcinos/prevención & control , Enfermedades de los Porcinos/virología , Proteínas del Envoltorio Viral/genéticaRESUMEN
To assess the correlation between the nature of immunity induced by different types of immunogens and the establishment of latent infection by wild-type pseudorabies virus (PrV), we used a murine model immunized with different immunogens, the PrV modified live vaccine (MLV), inactivated vaccine (IAV), and commercial oil-adjuvant subunit vaccine (OSV), via either intranasal (i.n.) or intramuscular (i.m.) route. Both MLV and IAV induced a different nature of immunity biased to Th1- and Th2-type, respectively, as judged by the ratio of PrV-specific IgG isotypes (IgG2a/IgG1) and the profile of cytokine IL-2, IL-4, and IFN-gamma production. In contrast, the OSV induced a lower isotype IgG2a to IgG1 ratio and higher level of IL-2 production. The MLV (inducing Th1-type) provided more effective protection against a virulent wild-type PrV challenge than IAV and OSV (inducing Th2- and mixed type, respectively). In addition, the MLV impeded the establishment of a latent infection with wild-type PrV, and the decrease in the PrV latency load by immunization with the MLV appeared to be mediated by the immune T-cells. These results demonstrate the substantial role of the immune responses driven by preceding vaccination in modulating the establishment of PrV latency caused by the post-infection of a field virus.
Asunto(s)
Herpesvirus Suido 1/inmunología , Vacunas contra la Seudorrabia/inmunología , Seudorrabia/prevención & control , Seudorrabia/virología , Latencia del Virus/fisiología , Animales , Anticuerpos Antivirales/sangre , Vías de Administración de Medicamentos , Femenino , Inmunoglobulina G/sangre , Ratones , Ratones Endogámicos C57BL , Seudorrabia/inmunología , Vacunas contra la Seudorrabia/administración & dosificaciónRESUMEN
Pseudorabies (PR) is an economically important viral disease of pigs which can infect numerous species of mammals including rodents. Commercial PR vaccines have been widely used worldwide to control and eradicate this disease. However, some PRV vaccines such as Bartha-K61 were occasionally reported to be lethal to mice. Since mice are commonly found in pig farms, the safety issue of PRV live vaccine across different species was never addressed. In this study, PRV vaccine strain Bartha-K61 was in vivo propagated in mice for five passages. The mortality of mice ranged from 80%-100% at each passage of PRV infection. The fifth passage of PRV was used to infect piglets to test its virulence on this species. The infected piglets clinically behaved normally and survived by the end of study (terminated at 10days post-infection). Histopathologically, there was infiltration of eosinophile granulocyte in tonsil and lung and no other changes were observed in other organs of infected pigs. Immunohistochemistry staining results showed that PRV antigen was only found in lung sample of one piglet. Therefore, the above results suggested there was no safety concern of Bartha-K61 PRV vaccine on pigs after the vaccine virus was passaged in mice for 5 times. The result of this study may suggest that mice may play a minimal role in the derivation of PRV vaccine-like field viruses that are believed to cause disease in young pigs.
Asunto(s)
Herpesvirus Suido 1/inmunología , Vacunas contra la Seudorrabia/administración & dosificación , Seudorrabia/prevención & control , Enfermedades de los Porcinos/prevención & control , Animales , Anticuerpos Antivirales/inmunología , Herpesvirus Suido 1/genética , Herpesvirus Suido 1/patogenicidad , Ratones , Ratones Endogámicos BALB C , Seudorrabia/virología , Vacunas contra la Seudorrabia/efectos adversos , Pase Seriado , Especificidad de la Especie , Sus scrofa , Porcinos , Enfermedades de los Porcinos/inmunología , Enfermedades de los Porcinos/virología , VirulenciaRESUMEN
Since late 2011, pseudorabies (PR) has resurfaced in many large pig farms, causing great economic loss for the swine industry in China. The PRV variant strain with high virulence and antigenic variation has been considered to be the main cause, and much attention has been focused on how to prevent and control the reoccurrence of this disease in China. In this study, two kinds of vaccination strategy were employed to evaluate the protective effects of Bartha-k61vaccine against both variant PRV (XJ5) and classical PRV (Ra) strain challenge. Humoral immunity response, clinical signs, survival rate, body weight, virus shedding and pathology were assessed in commercial pigs. The results showed that Bartha-k61vaccine, administered either once or twice, was effective against the PRV variant (XJ5) challenge, while no significant differences were observed between single and prime-boost vaccinated pigs. However, pigs vaccinated twice had better body weight gains than those vaccinated once, following challenge with the classical PRV strain (Ra) (p<0.01). Therefore, the Bartha-k61 vaccine appears to be an effective vaccine to control the spread of PRV variants in China in the absence of new powerful candidate vaccines specific to these PRV strains.
Asunto(s)
Anticuerpos Antivirales/biosíntesis , Herpesvirus Suido 1/efectos de los fármacos , Inmunidad Humoral/efectos de los fármacos , Vacunas contra la Seudorrabia/administración & dosificación , Seudorrabia/prevención & control , Vacunación , Animales , Variación Antigénica , Peso Corporal/efectos de los fármacos , Chlorocebus aethiops , Herpesvirus Suido 1/genética , Herpesvirus Suido 1/inmunología , Herpesvirus Suido 1/patogenicidad , Inmunización Secundaria , Inmunogenicidad Vacunal , Seudorrabia/inmunología , Seudorrabia/mortalidad , Seudorrabia/virología , Análisis de Supervivencia , Porcinos , Células Vero , Carga Viral/efectos de los fármacos , Virulencia , Esparcimiento de Virus/efectos de los fármacosRESUMEN
Glycoprotein B mediates the absorption and penetration of the pseudorabies virus in the form of an immunodominant Ag, and represents a major target for the development of new vaccines. This study evaluated the efficiency of live attenuated Salmonella typhimurium SL7207 for the oral delivery of DNA vaccine encoding the pseudorabies virus glycoprotein B (pCI-PrVgB) in vivo, leading to the generation of both systemic and mucosal immunity against the pseudorabies virus Ag. An oral transgene vaccination of pCI-PrVgB using a Salmonella carrier produced a broad spectrum of immunity at both the systemic and mucosal sites, whereas the intramuscular administration of a naked DNA vaccine elicited no mucosal immunoglobulin (Ig)A response. Interestingly, the Salmonella-mediated oral transgene vaccination of the pseudorabies virus glycoprotein B biased the immune responses to the Th2-type, as determined by the IgG2a/IgG1 ratio and the cytokine production profile. However, oral vaccination mediated by Salmonella harbouring pCI-PrVgB showed inferior protection to systemic immunization against virulent pseudorabies virus infection. The expression of transgene delivered by Salmonella bacteria in antigen-presenting cells of both the systemic and mucosal-associated lymphoid tissues was further demonstrated. These results highlight the potential use of live attenuated S. typhimurium for an oral transgene pseudorabies virus glycoprotein B vaccination to induce broad immune responses.
Asunto(s)
Vacunas contra la Seudorrabia/administración & dosificación , Salmonella typhimurium/inmunología , Vacunas de ADN/administración & dosificación , Proteínas del Envoltorio Viral/inmunología , Administración Oral , Animales , Femenino , Inmunidad Mucosa , Ratones , Seudorrabia/inmunología , Seudorrabia/prevención & control , Vacunas contra la Seudorrabia/inmunología , Vacunación , Vacunas Atenuadas , Vacunas de ADN/inmunología , Proteínas del Envoltorio Viral/administración & dosificación , Proteínas del Envoltorio Viral/genéticaRESUMEN
Porcine adenovirus (PAdV) has many qualities which make it an ideal choice for use as a delivery vector in swine. It is a low grade pathogen, present almost world-wide in a number of serotypes varying in their virulence and tissue tropism, which may allow for serotype specific vaccine targeting. PAdV is species specific having only been isolated from swine, reducing the possibility of its spread to other animals or man following administration. When engineered to contain a foreign gene, recombinant PAdV (rPAdV) can be grown to high titres in tissue culture cells making it cheap to produce. Knowledge of the complete nucleotide sequence of the PAdV genome has enabled rationally directed insertions of foreign genes which remain stably inserted in the genome and can be expressed at high levels following delivery to the target host. Importantly, recombinant PAdV can be administered by injection or by the oral route in feed or drinking water. We have delivered a range of antigens and immunomodulatory molecules to commercially available pigs using rPAdV and found it to be a very effective delivery system. Significantly, recombinant PAdV serotype 3 is highly effective as a delivery vehicle even when administered in the face of high levels of artificially induced serotype specific neutralising antibody to the vector.